Samsung Eyes $100M Investment in AI-Powered Medical Imaging Startup Exo

Samsung is preparing to invest up to $100 million in Exo, a pioneering medical imaging startup based in California. This potential funding round is led by Sands Capital, Bold Capital, and Qubit Health Capital, with Imar Ishrak, chairman of Qubit, set to join Exo’s board. The move signals Samsung’s strategic push into AI-driven healthcare technology.

Founded in 2015, Exo specializes in handheld medical imaging devices that combine artificial intelligence, advanced ultrasound technology, and silicon innovations. Their devices connect directly to smartphones, allowing medical professionals to perform lung scans, echocardiograms, and other ultrasound exams with ease. The integrated app facilitates scanning, documentation, and seamless sharing of exam reports.

Exo has already raised over $320 million from prominent investors including RA Capital Management, BlackRock, Intel, Sony, and Avidity Partners. Their last major funding was a $220 million Series C round in 2021, underscoring strong market confidence in their technology and growth potential.

In addition to the investment, Exo is reportedly in discussions to partner with Samsung Medison, a subsidiary specializing in ultrasound diagnostics and digital X-ray systems. This collaboration could accelerate the integration of Exo’s AI-powered imaging devices into broader medical diagnostic platforms.

Why This Matters

The convergence of AI and portable medical imaging is transforming healthcare delivery. Devices like Exo’s empower clinicians with real-time diagnostic capabilities at the point of care, improving patient outcomes and operational efficiency. Samsung’s investment reflects a broader industry trend toward integrating AI into medical devices to enhance precision and accessibility.

By embedding AI into handheld ultrasound tools, Exo is democratizing access to advanced diagnostics, especially in resource-limited settings. The smartphone interface simplifies data management and remote collaboration, a critical feature in today’s telemedicine-driven healthcare landscape.

For investors and healthcare providers, this technology represents a leap forward in cost-effective, scalable medical imaging solutions. Samsung’s involvement could accelerate product development cycles and expand global reach, fostering innovation in diagnostic care.

Looking Ahead

As AI continues to reshape medical technology, startups like Exo are at the forefront, blending innovation with practical healthcare applications. Samsung’s potential $100 million investment not only fuels Exo’s growth but also signals a commitment to advancing AI-powered diagnostics on a global scale.

This partnership could redefine how clinicians access and utilize imaging data, making diagnostics faster, more accurate, and more accessible than ever before.